Back to search

Article

Are Aspirin and Apixaban Sufficient to Prevent Immunothrombosis in COVID-19?

2020-12-29

Abstract excerpt

Severe COVID-19 disease is associated with respiratory and vascular injury and microvascular immunothrombosis mediated by complement activation, inflammatory lipid storm, platelet activation, platelet-leukocyte adhesion and activation of coagulation cascade. Amongst the inflammatory lipids, thromboxane A2 (TxA2) is a known key mediator of microvascular thrombosis. The levels of TxB2, a stable metabolite of TxA2 ar...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0d62f17c-dcde-5968-85aa-71ea87c3db3a
DOI
10.2139/ssrn.3755292
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Are Aspirin and Apixaban Sufficient to Prevent Immunothrombosis in COVID-19?DOI 10.2139/ssrn.3755292
Select a neighboring publication to make it the new centre.